Immunic to Participate in Investor, Scientific and Industry Conferences in June

NEW YORK, June 2, 2025 /PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced participation in the following investor, scientific and industry conferences in June:

Read more at prnewswire.com